FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3012106145> ?p ?o ?g. }

• W3012106145 endingPage "1156" @default.
• W3012106145 startingPage "1148" @default.
• W3012106145 abstract "Abstract KRAS mutation is a negative predictive biomarker of anti-EGFR agents in patients with metastatic colorectal cancer (mCRC), and remains an elusive target. Pelareorep, a double-stranded RNA virus selectively replicates in KRAS-mutated cells, and is synergistic with irinotecan. A dose escalation trial of FOLFIRI/bevacizumab [irinotecan (150–180 mg/m2) and pelareorep (1 × 1010 TCID50–3 × 1010 TCID50)] was implemented in adult patients with oxaliplatin refractory/intolerant, KRAS-mutant mCRC. Pelareorep was administered intravenously over 1 hour on days 1–5 every 4 weeks. Additional studies included pharmacokinetics, tumor morphology, and immune responses. Among FOLFIRI-naïve patients, the highest dose of FOLFIRI/bevacizumab (180 mg/m2 irinotecan) and pelareorep (3 × 1010 TCID50) was well tolerated, without a dose-limiting toxicity. At the recommended phase II dose, 3 of 6 patients (50%) had a partial response; the median progression-free and overall survival (PFS, OS) were 65.6 weeks and 25.1 months, respectively. Toxicities included myelosuppression, fatigue, and diarrhea. Transmission electron microscopy revealed viral factories (viral collections forming vesicular structures), at various stages of development. Immunogold staining against viral capsid σ-1 protein demonstrated viral “homing” in the tumor cells. The nucleus displayed sufficient euchromatin regions suggestive of active transcription. Flow cytometry revealed rapid dendritic cell maturation (48 hours) with subsequent activation of cytotoxic T cells (7 days). The combination of pelareorep with FOLFIRI/bevacizumab is safe. The PFS and OS data are encouraging and deserve further exploration. Pelareorep leads to a clear recurrent immune stimulatory response with cytotoxic T-cell activation, and homes and replicates in the tumor." @default.
• W3012106145 created "2020-03-23" @default.
• W3012106145 creator A5006031207 @default.
• W3012106145 creator A5020487673 @default.
• W3012106145 creator A5029455802 @default.
• W3012106145 creator A5036497390 @default.
• W3012106145 creator A5049924653 @default.
• W3012106145 creator A5069675476 @default.
• W3012106145 creator A5071271988 @default.
• W3012106145 creator A5071784908 @default.
• W3012106145 creator A5073337703 @default.
• W3012106145 creator A5083949476 @default.
• W3012106145 date "2020-05-01" @default.
• W3012106145 modified "2023-10-14" @default.
• W3012106145 title "Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with <i>KRAS</i>-Mutated Colorectal Cancer" @default.
• W3012106145 cites W1507621459 @default.
• W3012106145 cites W1749496846 @default.
• W3012106145 cites W1936207051 @default.
• W3012106145 cites W1972692268 @default.
• W3012106145 cites W2015148142 @default.
• W3012106145 cites W2019607817 @default.
• W3012106145 cites W2021192823 @default.
• W3012106145 cites W2028577286 @default.
• W3012106145 cites W2071260213 @default.
• W3012106145 cites W2085633477 @default.
• W3012106145 cites W2090599158 @default.
• W3012106145 cites W2110410873 @default.
• W3012106145 cites W2112270226 @default.
• W3012106145 cites W2115735904 @default.
• W3012106145 cites W2120067300 @default.
• W3012106145 cites W2121847974 @default.
• W3012106145 cites W2147834058 @default.
• W3012106145 cites W2156894217 @default.
• W3012106145 cites W2160373161 @default.
• W3012106145 cites W2163045779 @default.
• W3012106145 cites W2163492712 @default.
• W3012106145 cites W2164991354 @default.
• W3012106145 cites W2167539263 @default.
• W3012106145 cites W2252545871 @default.
• W3012106145 cites W2262414037 @default.
• W3012106145 cites W2316101052 @default.
• W3012106145 cites W242040007 @default.
• W3012106145 cites W2781931068 @default.
• W3012106145 cites W2792344809 @default.
• W3012106145 cites W2792539640 @default.
• W3012106145 cites W2793868664 @default.
• W3012106145 cites W2802981934 @default.
• W3012106145 cites W2807847969 @default.
• W3012106145 cites W2988731068 @default.
• W3012106145 doi "https://doi.org/10.1158/1535-7163.mct-19-1117" @default.
• W3012106145 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7207225" @default.
• W3012106145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32156785" @default.
• W3012106145 hasPublicationYear "2020" @default.
• W3012106145 type Work @default.
• W3012106145 sameAs 3012106145 @default.
• W3012106145 citedByCount "20" @default.
• W3012106145 countsByYear W30121061452020 @default.
• W3012106145 countsByYear W30121061452021 @default.
• W3012106145 countsByYear W30121061452022 @default.
• W3012106145 countsByYear W30121061452023 @default.
• W3012106145 crossrefType "journal-article" @default.
• W3012106145 hasAuthorship W3012106145A5006031207 @default.
• W3012106145 hasAuthorship W3012106145A5020487673 @default.
• W3012106145 hasAuthorship W3012106145A5029455802 @default.
• W3012106145 hasAuthorship W3012106145A5036497390 @default.
• W3012106145 hasAuthorship W3012106145A5049924653 @default.
• W3012106145 hasAuthorship W3012106145A5069675476 @default.
• W3012106145 hasAuthorship W3012106145A5071271988 @default.
• W3012106145 hasAuthorship W3012106145A5071784908 @default.
• W3012106145 hasAuthorship W3012106145A5073337703 @default.
• W3012106145 hasAuthorship W3012106145A5083949476 @default.
• W3012106145 hasBestOaLocation W30121061451 @default.
• W3012106145 hasConcept C111113717 @default.
• W3012106145 hasConcept C112705442 @default.
• W3012106145 hasConcept C121608353 @default.
• W3012106145 hasConcept C126322002 @default.
• W3012106145 hasConcept C143998085 @default.
• W3012106145 hasConcept C154317977 @default.
• W3012106145 hasConcept C202751555 @default.
• W3012106145 hasConcept C203014093 @default.
• W3012106145 hasConcept C2776694085 @default.
• W3012106145 hasConcept C2776705615 @default.
• W3012106145 hasConcept C2777802072 @default.
• W3012106145 hasConcept C2780259306 @default.
• W3012106145 hasConcept C2780962732 @default.
• W3012106145 hasConcept C2781187634 @default.
• W3012106145 hasConcept C502942594 @default.
• W3012106145 hasConcept C526805850 @default.
• W3012106145 hasConcept C55493867 @default.
• W3012106145 hasConcept C71924100 @default.
• W3012106145 hasConcept C86803240 @default.
• W3012106145 hasConcept C98274493 @default.
• W3012106145 hasConceptScore W3012106145C111113717 @default.
• W3012106145 hasConceptScore W3012106145C112705442 @default.
• W3012106145 hasConceptScore W3012106145C121608353 @default.
• W3012106145 hasConceptScore W3012106145C126322002 @default.
• W3012106145 hasConceptScore W3012106145C143998085 @default.
• W3012106145 hasConceptScore W3012106145C154317977 @default.

• next